Suzhou Zelgen Biopharmaceuticals Company Description

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China.

It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.

The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Country	China
Founded	2009
Industry	Biotechnology
Sector	Healthcare
Employees	910
CEO	Zelin Sheng

Contact Details

Address: No. 209, Chenfeng Road Kunshan, 215300 China
Phone	86 512 5701 8310
Website	zelgen.com

Stock Details

Ticker Symbol	688266
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100003RP1
SIC Code	2836

Key Executives

Name	Position
Zelin Sheng	Chairman of the Board and GM
Gang Huang	Chief Financial Officer and Deputy GM
Zeqi Sheng	Chief Scientific Officer
Huiping Lu	Executive Vice President and Director
Jisheng Wu	Director and Deputy GM
Binhua Lyu	Deputy GM, Executive Vice President of Chemistry and Director
Qingping Gao	Deputy GM and Board Secretary
Shice Shao	Accounting Supervisor